

# IMMUNE CHECKPOINT INHIBITION AND CHEMOTHERAPY IN NSCLC AND BREAST CANCER: A FLAMENCO OR A TANGO?

**MONDAY, 10 OCTOBER 2016**  
18:30-20:00

**COPENHAGEN DENMARK**  
ROOM: MADRID

## **Chairs**

Jean-Yves Douillard, Lugano, Switzerland  
Christoph Zielinski, Vienna, Austria



The ESMO Colloquia are innovative new sessions within the Congress programme that bring together top experts to discuss evolving areas of interest to the oncology community. The Colloquia are organised by ESMO and supported by the industry and are unique collaborations offering early access to ground-breaking studies, making them the perfect complement to the scientific and educational programme of the Congress.

This ESMO Colloquium will be awarded 1 ESMO MORA point.

The ESMO Colloquium **Immune checkpoint inhibition and chemotherapy in NSCLC and breast cancer** is provided by ESMO and supported by Celgene.



# IMMUNE CHECKPOINT INHIBITION AND CHEMOTHERAPY IN NSCLC AND BREAST CANCER

## RATIONALE AND OBJECTIVES

- To learn about the biology of the immune cancer response, including immune cytotoxic and escape mechanisms
- To understand the evolving role of biomarkers for better patient selection and personalised treatment with immune checkpoint inhibitors
- To appreciate the differences in clinical outcomes according to tumour types
- To understand the factors involved in the modulation of activity and the development of resistance

## MONDAY, 10 OCTOBER 2016

---

*Chairs: Jean-Yves Douillard, Lugano, Switzerland  
Christoph Zielinski, Vienna, Austria*

---

- 18:30 Introduction  
*Christoph Zielinski, Vienna, Austria*
- 18:35 Immunology of tumours and their microenvironment: Clinical implications, the emergence of resistance and the evolution of biomarkers  
*Maria Sibilia, Vienna, Austria*
- 18:55 Checkpoint inhibition treatment: Two very different siblings?
  - **Breast cancer**  
*Sibylle Loibl, Neu-Isenburg, Germany*
  - **Lung cancer**  
*Luis Paz-Ares, Madrid, Spain*
- 19:35 Modulation response to checkpoint inhibitor treatment immunomodulatory combinations, methylation treatment and the role of chemotherapy  
*Johan Vansteenkiste, Leuven, Belgium*
- 19:25 Conclusions  
*Jean-Yves Douillard, Lugano, Switzerland*

## **SPEAKERS**



**Prof. Jean-Yves Douillard,**  
Lugano, Switzerland  
ESMO Chief Medical Officer

Professor Jean-Yves Douillard received his medical training at the University of Nantes Medical School and completed his PhD in 1993. He was the recipient of a fellowship from the French Ministry of Health and the US National Institutes of Health John E. Fogarty International Center for Advanced Study in the Health Sciences.

He completed two years as a visiting Fellow at the National Cancer Institute's Laboratory of Immunodiagnosis, before returning to France to accept the position of Assistant Professor in Medical Oncology at the University of Nantes. He spent a further two years as a visiting scientist at the US Food and Drug Administration Center for Biologics Evaluation and Research at the National Institute of Health, Bethesda and Rockville, MD, USA. Previously, he was Head of the Department of Medical Oncology (2000–2009) and Director of Clinical and Translational Research (2009–2011) at the Integrated Centres of Oncology R. Gauducheau, and then was Professor of Medical Oncology and Senior Staff Physician at the Integrated Centres of Oncology R. Gauducheau and the University of Nantes Medical School, Nantes, France.

His clinical trial involvement focuses mainly on lung cancer and gastrointestinal tumours, and has included investigations of several new drugs, as well as targeted therapies.

In March 2016 he was appointed ESMO's first Chief Medical Officer. He is a member of ASCO, AACR, ESMO and the French Co-Operative Thoracic Intergroup. He is an Associate Editor for *ESMO Open* and has published numerous articles in prestigious scientific journals, including *The Lancet*, *the New England Journal of Medicine*, *the Journal of Clinical Oncology*, *The Lancet Oncology*, *the British Journal of Cancer*, *Cancer Research*, *the European Journal of Cancer*, *Annals of Oncology* and *the Journal of Thoracic Oncology*.

## SPEAKERS

**ESMO**  
COLLOQUIA



**Prof. Sibylle Loibl**  
Neu-Isenburg, Germany

Chair of the German Breast Group, Associate Professor of gynaecology and obstetrics, University of Frankfurt/Main, Germany

Professor Sibylle Loibl, MD, PhD, is the Chair of the German Breast Group, one of the leading cooperative groups world-wide in breast cancer and an Associate Professor of gynaecology and obstetrics at the University of Frankfurt/Main in Germany and a renowned international breast cancer specialist. Her work focuses on young women especially breast cancer during pregnancy where she led several guideline publications. Another field of interest is neoadjuvant therapy with a focus on translational research.

She has designed and led a large number of national and international clinical trials in breast cancer in all settings. Professor Loibl has contributed with the GBG to the improvement of the infrastructure for breast cancer trials all over Germany.

Professor Loibl has authored and co-authored more than 230 Medline-listed scientific papers, in addition to more than 190 original and peer-reviewed articles, and 40 books or book chapters. She has also actively contributed to more than 170 national and international congresses. She serves on the board of several peer-reviewed journals. Professor Loibl is an active member of several national and international organizations and guideline committees.

## **SPEAKERS**



**Prof. Luis Paz-Ares**  
Madrid, Spain

Chair of the Medical Oncology Department, Hospital Doce de Octubre, Associate Professor Universidad Computense, and Head of the Lung Cancer Unit at the National Oncology Research Center (CNIO), Madrid, Spain

Professor Luis Paz-Ares is currently Chair of the Medical Oncology Department at the Hospital Doce de Octubre, Associate Professor at the Universidad Complutense, and Head of the Lung Cancer Unit at the CNIO (National Oncology Research Center), all in Madrid, Spain.

He graduated with a degree in Medicine from the Universidad Autonoma de Madrid, in 1986, and completed a PhD in 1993 at the same university. He was a postdoctoral ESMO Research Fellow in Medical Oncology at the Beatson Oncology Centre, University of Glasgow, Glasgow, Scotland (1993–1995), and completed a Master's degree in Clinical Pharmacology at the University of Glasgow in 1995. Luis Paz-Ares also completed a Master's degree in Clinical Unit Management at the UNED-Fundación Universidad Empresa (2002–2003).

Prior to his current position, he was Chair of the Medical Oncology Department at the Virgen del Rocío University Hospital in Seville (2007–2014), Head of the Pharmacology Unit and responsible for early clinical studies of thoracic and genitourinary tumours at the University Hospital “12 de Octubre” in Madrid (1995–1999; 2000–2007), and Visiting Research Fellow in the Prostate Cancer Programme at the Dana-Farber Cancer Institute in Boston, MA, USA (1999–2000).

Luis Paz-Ares's research focuses on lung cancer and new therapeutic strategies development, both at the lab and clinical sides, and has published more than 240 papers in peer reviewed journals, as well as many book chapters, including *New England Journal of Medicine*, *Lancet*, *Lancet Oncology*, *Journal of Clinical Oncology* and many others.

He is an active member of various scientific societies (including ASCO, ESMO, IASLC and other) and collaborative groups (European Organisation for Research and Treatment of Cancer [EORTC], the Spanish Lung Cancer Group and the International Germ Cell Cancer Collaborative Group).

## SPEAKERS

**ESMO**  
COLLOQUIA



**Prof. Maria Sibilia**  
Vienna, Austria

Head of the Institute of Cancer Research and Coordinator of basic and translational research of the Comprehensive Cancer Center at the Medical University of Vienna

Professor Maria Sibilia, PhD is Full professor for Cellular and Molecular Tumor Biology, the Head of the Institute of Cancer Research and the Coordinator of basic and translational research of the Comprehensive Cancer Center at the Medical University of Vienna. She received, among others, the Prize of the City of Vienna for Medical Sciences, the Otto Kraupp Prize for the best Habilitation in Austria and the Alois Sonnleitner Prize of the Austrian Academy of Science for outstanding achievements in cancer research.

In 2012 she was elected an EMBO member and 2013 as corresponding member of the Austrian Academy of Sciences. She is a member of various professional biomedical research boards such as the Austrian Science Fund (FWF) and coordinator of the PhD program "Inflammation and Immunity". Since 2016 she holds an advanced ERC grant to investigate novel therapeutic approaches to enhance immunity against tumors.

## **SPEAKERS**



**Prof. Johan Vansteenkiste**  
Leuven, Belgium

Professor of Internal Medicine in the Faculty of Medicine at the Catholic University of Leuven, Belgium, and Head of Clinic in the Respiratory Oncology Unit and its Clinical Trial Unit at the Leuven University Hospital

Professor Johan Vansteenkiste is Professor of Internal Medicine in the Faculty of Medicine at the Catholic University of Leuven, Belgium, and Head of Clinic in the Respiratory Oncology Unit and its Clinical Trial Unit at the Leuven University Hospital.

Professor Vansteenkiste studied Medicine at the University of Leuven before becoming a Board Certified Pulmonologist-Oncologist. He had additional training in Respiratory Oncology at the European School of Oncology in Milan, Italy, and in Respiratory Endoscopy at the Laser Centre in Marseille, France, before gaining his PhD at the University of Leuven in 1996.

Professor Vansteenkiste is an active member of different international societies such as ESMO, IASLC, ASCO, ERS and others. He was Secretary of the Thoracic Oncology Assembly of the ERS and member of the ERS School Board in 2009-2012. He was member of the Board of Directors of IASLC in 2009-2013. He is member of the ESMO Lung Educational Group and Guidelines Group, and chaired the European Lung Cancer Conference in March 2015.

He is the principal investigator or co-investigator in several clinical trials in the area of lung cancer. He is Associate Editor at *Annals of Oncology*, member of the editorial board of several other journals, and author or co-author of about 300 peer-reviewed papers and book chapters on Respiratory Oncology.



## SPEAKERS

ESMO  
COLLOQUIA



**Prof. Christoph Zielinski**  
Vienna, Austria

Director Clinical Division of Oncology, Chairman of Department of Medicine I at Medical University Vienna, Austria. Coordinator of the Comprehensive Cancer Center at Medical University Vienna and the General Hospital in Vienna, Austria

Professor Zielinski is Director of the Clinical Division of Oncology and Chairman of the Department of Medicine I at Medical University Vienna, Austria. He serves as Coordinator of the Comprehensive Cancer Center at Medical University Vienna and the General Hospital in Vienna, Austria, and is President of the Central European Cooperative Oncology Group ((CECOG).

Professor Zielinski, MD, PhD, completed his medical training at the University Hospital Vienna in 1986 and began his career with a position as a research fellow at the Cancer Research Center at Tufts University, Boston, USA. His recent clinical research activities cover a wide range of cancer therapies, with particular focus on clinical trials, breast and lung cancer research and treatment and development of targeted drugs. He has published 430 original papers and reviews in peer-reviewed journals and has served as the editor of the German Edition of the *Journal of Clinical Oncology*. He is member of the editorial board of numerous peer-reviewed journals. In 2015 he became Editor-in-Chief of *ESMO Open*, ESMO's open-access, peer reviewed online-only journal.

Professor Zielinski is a member of the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR) and the European Society for Medical Oncology (ESMO).

Professor Zielinski has served on a series of ESMO committees and was the Local Officer for the ESMO Congress 2012 in Vienna, Austria. Professor Zielinski has been a member of the ESMO Executive Board since 2014.

## SUGGESTED READING MATERIAL

- Bedognetti D, Maccalli C, Bader SB, Marincola FM, Seliger B. Checkpoint Inhibitors and Their Application in Breast Cancer. *Breast Care* (Basel). 2016 Apr;11(2):108-15. doi: 10.1159/000445335. Epub 2016 Apr 26. Review. PMID: 27239172
- Chabanon RM, Pedrero M, Lefebvre C, Marabelle A, Soria JC, Postel-Vinay S. Mutational Landscape and Sensitivity to Immune Checkpoint Blockers. *Clin Cancer Res*. 2016 Sep 1;22(17):4309-21. doi: 10.1158/1078-0432.CCR-16-0903. Epub 2016 Jul 7. Review. PMID: 27390348
- Hiley CT, Le Quesne J, Santis G, Sharpe R, de Castro DG, Middleton G, Swanton C. Challenges in molecular testing in non-small-cell lung cancer patients with advanced disease. *Lancet*. 2016 Sep 3;388(10048):1002-11. doi: 10.1016/S0140-6736(16)31340-X. Epub 2016 Sep 1. Review. PMID: 27598680
- Manson G, Norwood J, Marabelle A et al. Biomarkers associated with checkpoint inhibitors. *Ann Oncol* 2016; 27: 1199-1206.
- Pardoll D. Cancer and the Immune System: Basic Concepts and Targets for Intervention. *Semin Oncol*. 2015 Aug;42(4):523-38. doi: 10.1053/j.seminoncol.2015.05.003. Epub 2015 Jun 3. Review.
- Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. *Cell*. 2015 Apr 9;161(2):205-14. doi: 10.1016/j.cell.2015.03.030. Review. PMID: 25860605

The ESMO Colloquium **Immune checkpoint inhibition and chemotherapy in NSCLC and breast cancer** is provided by ESMO and supported by Celgene.

